Form 8-K - Current report:
SEC Accession No. 0001193125-24-079600
Filing Date
2024-03-28
Accepted
2024-03-28 07:06:30
Documents
15
Period of Report
2024-03-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d816795d8k.htm   iXBRL 8-K 25167
2 EX-99.1 d816795dex991.htm EX-99.1 51613
6 GRAPHIC g816795g0327201432490.jpg GRAPHIC 3604
  Complete submission text file 0001193125-24-079600.txt   213279

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA grtx-20240328.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE grtx-20240328_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grtx-20240328_pre.xml EX-101.PRE 11261
18 EXTRACTED XBRL INSTANCE DOCUMENT d816795d8k_htm.xml XML 3632
Mailing Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355
Business Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

EIN.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39114 | Film No.: 24793462
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)